Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LFX453 in Healthy Volunteers
NCT02052687Phase 1Completed
- Sponsor
- Novartis
- Start
- Jan 2014
- Primary completion
- Jun 2014
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LFX453 in actinic keratosis (AK) (6 arms), sponsored by Novartis. Primary endpoints: General safety (number of subjects with adverse events) at 14 days and Local skin tolerability (tolerability score) at 14 days. Started Jan 2014; status: completed.
02
Drugs
LFX453
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02052687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052687.